Related Experiment Video

Updated: Jul 10, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

[Biotherapy of cancer by anti-EGFR monoclonal antibody]

Jing Wang1, Zhi-Yun Meng, Sou-Ting Fu

  • 1Key Laboratory of Pharmacokinetics, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|October 25, 2007
PubMed

Insights

Three anti-EGFR monoclonal antibodies show promise for treating epithelial cancers by targeting epidermal growth factor receptor (EGFR). Clinical studies and pharmacokinetics of cetuximab, panitumumab, and nimotuzomab were reviewed.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) plays a crucial role in epithelial malignancies.
  • EGFR mutations, dysregulation, and overexpression are common in various cancers, driving tumor growth and progression.

Purpose of the Study:

  • To review the pharmacokinetics and clinical studies of three anti-EGFR monoclonal antibodies.
  • To evaluate the anti-tumor potential and side effect profiles of targeted EGFR therapies.

Main Methods:

  • Literature review of pharmacokinetic data.
  • Analysis of clinical trial results for specified anti-EGFR antibodies.

Main Results:

  • Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR.
  • These antibodies demonstrate promising anti-tumor activity in clinical trials.
  • The reviewed therapies exhibit a favorable safety profile with no severe side effects.

Conclusions:

  • Cetuximab, panitumumab, and nimotuzomab are effective anti-EGFR monoclonal antibodies.
  • These agents hold significant therapeutic potential for epithelial cancers.
  • Targeting EGFR offers a promising strategy for cancer treatment with manageable side effects.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...